All In Biotech

NDA 219531 · Brillian Pharma

Sdamlo

Amlodipine Besylate · Oral

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 24, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

656

178 Phase 3, 22 recruiting

FAERS reports

272,542

210,815 serious, 29,856 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 28, 2026.

Sdamlo is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Sdamlo is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease in adults ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40% 1.1 Hypertension Sdamlo is indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in...

Mechanism: Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SDAMLO · AMLODIPINE BESYLATE EQ 10MG BASE/BOT · FOR SOLUTION, ORAL · Prescription
  • SDAMLO · AMLODIPINE BESYLATE EQ 2.5MG BASE/BOT · FOR SOLUTION, ORAL · Prescription
  • SDAMLO · AMLODIPINE BESYLATE EQ 5MG BASE/BOT · FOR SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amlodipine" as an intervention, any sponsor and status, largest first.

All 656 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue16,575
  • diarrhoea14,878
  • nausea14,107
  • dyspnoea13,787
  • drug ineffective12,840
  • off label use12,053
  • dizziness11,278
  • headache10,422
  • acute kidney injury9,953
  • pain9,609
  • vomiting9,269
  • fall8,925

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004744
2005878
20061,036
20071,407
20081,912
20093,213
20104,129
20115,415
20127,098
20137,601
201410,322
201514,615
201616,314
201718,466
201822,937
201924,686
202023,025
202120,651
202218,616
202319,071
202417,911
202518,330
202614,164

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,807 on PubMed

Sponsor: Brillian Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.